Sustainability
Society
Human Rights
At Hisamitsu Pharmaceutical, not only do we comply with the laws and regulations of various countries and regions, but we also respect human rights and recognize our responsibilities to conduct business operations that will contribute to society. We perform human rights due diligence on a continual basis and respect the human rights of people all over the world, thereby contributing to the development of a sustainable society and the sustainability of the entire globe.
Hisamitsu Pharmaceutical Group Human Rights Policy
Hisamitsu Pharmaceutical established the Hisamitsu Pharmaceutical Human Rights Policy in March 2018, based on the United Nations Guiding Principles on Business and Human Rights, and revised it to the Hisamitsu Pharmaceutical Group Human Rights Policy in June 2024. In revising it, we once again strived to enhance our understanding of and respect for human rights declared in the International Bill of Human Rights established by the United Nations (Universal Declaration of Human Rights, International Covenant on Civil and Political Rights, and International Covenant on Economic, Social and Cultural Rights), the core labor standards in the ILO (International Labour Organization) Declaration on Fundamental Principles and Rights at Work that specifies basic rights at work, and the Declaration of Helsinki by the World Medical Association (hereinafter collectively referred to as “International Principles of Human Rights”).The Corporate Philosophy of the Hisamitsu Pharmaceutical Group is “Delivering a Better QOL to the World” through the creation, development, manufacture, and sales of pharmaceuticals and other products. The Hisamitsu Group has also established its Company Mission as “Promoting ‘TE-A-TE’ Culture Worldwide.” Based on this philosophy and mission, the Hisamitsu Group will actively expand its activities to promote the “TE-A-TE” culture of compassion for people all over the world through not only transdermal patches but also various other products and services.Respecting the human rights in our value chain across the Hisamitsu Group’s business activities is consistent with our Corporate Philosophy, and thus we will push ahead together with our group companies and stakeholders, including our business partners.
Hisamitsu Pharmaceutical Group Human Rights Policy (excerpt)
| Human Rights Due Diligence | The Hisamitsu Group conducts human rights due diligence on an ongoing basis in order to identify negative human rights impacts related to our business activities and prevent or reduce them. |
|---|---|
| Dialog and Consultation with Stakeholders | The Hisamitsu Group promotes commitment to identifying issues of human rights and respecting human rights through dialogues and talks with related stakeholders. |
| Education and Training | The Hisamitsu Group provides all executives and employees with appropriate education and training so that this policy can be understood and implemented effectively. |
| Relief | The Hisamitsu Group shall, if it becomes clear that we have caused or encouraged negative impacts on human rights, work to offer relief from that through appropriate procedures. |
| Information Disclosure | The Hisamitsu Group discloses information on our commitment to respecting human rights through our website. |
| Applicable Laws and Ordinances | Hisamitsu Group complies with applicable laws and ordinances in each country and region where it operates. However, if there is any inconsistency between the laws and regulations of a country/region and the internationally recognized principles of human rights, we shall pursue methods that fully respect the internationally recognized principles of human rights. |
Compliance with UK Modern Slavery Act
Statement on the UK Modern Slavery Act is available on our website.
Hisamitsu Pharmaceutical is committed to respecting internationally recognized human rights, including the prevention of slavery and human trafficking in our business and supply chain.
Sustainability Procurement
From FY2021, we conduct the web-based Self-Assessment Questionnaire (SAQ) every year with our primary and secondary suppliers of our products manufactured at factories in Japan to confirm the current status and assess risks with regard to human rights and labor, safety and health, environment, and compliance. We also started SAQ for primary and secondary suppliers of products manufactured at the factories of Hisamitsu Indonesia in FY2022 and those of Hisamitsu Vietnam, Noven, and Hisamitsu Brazil in FY2023. In FY2024, we conducted SAQ for primary and secondary suppliers of products manufactured at all domestic and overseas factories.We use the SAQ to understand the current situation and assess risks at our suppliers, and we request that primary and secondary suppliers make corrections if we deem it necessary.We will continue to prevent and mitigate human rights risks in our supply chain through these efforts.
